search
Back to results

CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)

Primary Purpose

Diabetes Mellitus, Type II

Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Duvie Tab. 0.5mg
Duvie Tab. 0.5mg + Januvia Tab. 100mg
Sponsored by
Chong Kun Dang Pharmaceutical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type II

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. A healthy male whose age is over 19 years old when visiting for initial screening test
  2. Body mass index(BMI) between 17.5~30.5 kg/m^2 and the body weight must be over 55kg (Body mass index (BMI) = weight (kg) / height (m)^2)
  3. A male with no congenital or chronic disease in three years, no history of symptoms in internal treatment, or no knowledge in the area
  4. Due to the special characteristics of drugs, the participators must be qualified to do the clinical screening after examined through hematology test and blood chemistry analysis, urinary test, the electrocardiogram (ECG), and etc.
  5. The participants must be volunteered and sign in an informed consent document proven by Chonbuk National University IRB before joining a study to show that he was given informed the purpose of tests and the special characteristics of drugs.
  6. The participants must have an ability and willingness to participate throughout the entire trials

Exclusion Criteria:

  1. A person who had a history or symptoms of clinically aware of blood, kidney, internal secretion, gastrointestinal, urinary system, cardiovascular, liver, mental, nercous, or allergic(except subclinical seasonal allergies that is not treated at injecion) desease.
  2. Who had a gistory of gastrointestinal related disease which can be affected the drug absorption (esophageal achalasia, esophagostenosis, esophageal disease, or Crohn's disease) or surgeries (except a simple appendectomy or herniotomy)
  3. Who had following results after examination

    a. ALT or AST > twice higher than normal value

  4. Who constantly intake 210 g/week of alcohol within 6 months of the screening. (a cup of beer (5%) (250 mL) = 10 g, a shot of soju (20%) (50mL) = 8 g, a glass of wine (!2%) (125 mL) = 12g)
  5. Who participated other clinical test or took testing bioequivalence drugs in 3 months before the first clinical drug trial.
  6. Whose blood pressure ≤ 100 or ≥150(systolic blood pressure) or < 60 or ≥ 100(diastolic blood pressure)
  7. Who had a medical history of alcohol and drug abuses.
  8. Who had taken a drug that has a control of metabolic rate (activatioh or inhibithion) in 30 days before the first taking of clinical testing durg.
  9. WHo smokes more than 20 eigarettes per day.
  10. Who took prescribed drugs or over-the-conuter durgs in 10 days before taking of very first clinical testing drug.
  11. Who participated in whole blood donation in 2 months before the first taking of clinical testing drugs or platelet donations in 1 month before the first taking to clinical testing drugs.
  12. Who has a potent to increase a danger by participating in the clinical trials or sho can interrupt interpretin test results by having serious or chronic medical and mental status or having issues in results of the screening examination.
  13. Who has a histroy of an extreme sensitivity of drugs that contain Rosiglitazone or dugs that have similar effect a Rosiglitazone(Pioglitazone), or drugs that contain the ingredients of Sitagliptin or thiazolidinediones drugs.
  14. Who has a serious heart failure or a congestive heart failure that must be drug-treated
  15. A patient with hepatopathy.
  16. A patient with wevere nephropathy.
  17. Who has diabetic ketoacidosis or a diaetic coma, or type 1 diabetes, or has history of acute metablic acidosis or ketoacidosis.
  18. A patient with serious infectious disease or severe injuries before and after a surgery.
  19. Who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose malabsorption or genetic disorders.
  20. Test subjects who is not willing or unable to comply with guidelines described in this protocol.
  21. A person who is not determined unsuitable to participate in this test by the researchers.

Sites / Locations

  • Chonbuk National University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Group 1(Treatment A/Treatment B)

Group 2(Treatment B/Treatment A)

Arm Description

Period 1: Treatment A(Duvie Tab. 0.5mg)*1T/day for 5 days, QD, PO Period 2: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO Each treatment period was separated by a washout period of at least 10 dyas.

Period 1: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO Period 2: Treatment A(Duvie Tab. 0.5mg)*1T/day for 5 days, QD, PO Each treatment period was separated by a washout period of at least 10 dyas.

Outcomes

Primary Outcome Measures

AUCτ of Lobeglitazone
Css,max of Lobeglitazone

Secondary Outcome Measures

Css,min of Lobeglitazone
Css,av of Lobeglitazone
Tss,max of Lobeglitazone
t1/2 of Lobeglitazone
CLss/F of Lobeglitazone
Vdss/F of Lobeglitazone
fluctuation[(Css,max-Css,min)/Css,av] of Lobeglitazone
swing[(Css,max-Css,min)/Css,min] of Lobeglitazone

Full Information

First Posted
June 30, 2016
Last Updated
July 6, 2016
Sponsor
Chong Kun Dang Pharmaceutical
search

1. Study Identification

Unique Protocol Identification Number
NCT02824874
Brief Title
CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)
Official Title
A Randomized, Open-label, Multiple Dosing, 2-way Crossover Study to Evaluate the Effect of Sitagliptin on Pharmacokinetics of Lobeglitazone in Healthy Male Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
July 2016
Overall Recruitment Status
Completed
Study Start Date
April 2016 (undefined)
Primary Completion Date
April 2016 (Actual)
Study Completion Date
May 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chong Kun Dang Pharmaceutical

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate a pharmacokinetic drug interaction between lobeglitazone and sitagliptin in healthy male volunteers.
Detailed Description
To healthy male subjects of twenty(20), following treatments are administered dosing in each period and wash-out period is a minimum of 10 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type II

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group 1(Treatment A/Treatment B)
Arm Type
Experimental
Arm Description
Period 1: Treatment A(Duvie Tab. 0.5mg)*1T/day for 5 days, QD, PO Period 2: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO Each treatment period was separated by a washout period of at least 10 dyas.
Arm Title
Group 2(Treatment B/Treatment A)
Arm Type
Experimental
Arm Description
Period 1: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO Period 2: Treatment A(Duvie Tab. 0.5mg)*1T/day for 5 days, QD, PO Each treatment period was separated by a washout period of at least 10 dyas.
Intervention Type
Drug
Intervention Name(s)
Duvie Tab. 0.5mg
Other Intervention Name(s)
Lobeglitazone 0.5mg
Intervention Description
Duvie Tab. 0.5mg*1T/day for 5days, QD, PO
Intervention Type
Drug
Intervention Name(s)
Duvie Tab. 0.5mg + Januvia Tab. 100mg
Other Intervention Name(s)
Lobeglitazone 0.5mg + Sitagliptin 100mg
Intervention Description
Duvie Tab. 0.5mg + Januvia Tab.100mg*1T/day for 5 dyas, QD, PO
Primary Outcome Measure Information:
Title
AUCτ of Lobeglitazone
Time Frame
1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h
Title
Css,max of Lobeglitazone
Time Frame
1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h
Secondary Outcome Measure Information:
Title
Css,min of Lobeglitazone
Time Frame
1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h
Title
Css,av of Lobeglitazone
Time Frame
1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h
Title
Tss,max of Lobeglitazone
Time Frame
1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h
Title
t1/2 of Lobeglitazone
Time Frame
1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h
Title
CLss/F of Lobeglitazone
Time Frame
1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h
Title
Vdss/F of Lobeglitazone
Time Frame
1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h
Title
fluctuation[(Css,max-Css,min)/Css,av] of Lobeglitazone
Time Frame
1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h
Title
swing[(Css,max-Css,min)/Css,min] of Lobeglitazone
Time Frame
1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: A healthy male whose age is over 19 years old when visiting for initial screening test Body mass index(BMI) between 17.5~30.5 kg/m^2 and the body weight must be over 55kg (Body mass index (BMI) = weight (kg) / height (m)^2) A male with no congenital or chronic disease in three years, no history of symptoms in internal treatment, or no knowledge in the area Due to the special characteristics of drugs, the participators must be qualified to do the clinical screening after examined through hematology test and blood chemistry analysis, urinary test, the electrocardiogram (ECG), and etc. The participants must be volunteered and sign in an informed consent document proven by Chonbuk National University IRB before joining a study to show that he was given informed the purpose of tests and the special characteristics of drugs. The participants must have an ability and willingness to participate throughout the entire trials Exclusion Criteria: A person who had a history or symptoms of clinically aware of blood, kidney, internal secretion, gastrointestinal, urinary system, cardiovascular, liver, mental, nercous, or allergic(except subclinical seasonal allergies that is not treated at injecion) desease. Who had a gistory of gastrointestinal related disease which can be affected the drug absorption (esophageal achalasia, esophagostenosis, esophageal disease, or Crohn's disease) or surgeries (except a simple appendectomy or herniotomy) Who had following results after examination a. ALT or AST > twice higher than normal value Who constantly intake 210 g/week of alcohol within 6 months of the screening. (a cup of beer (5%) (250 mL) = 10 g, a shot of soju (20%) (50mL) = 8 g, a glass of wine (!2%) (125 mL) = 12g) Who participated other clinical test or took testing bioequivalence drugs in 3 months before the first clinical drug trial. Whose blood pressure ≤ 100 or ≥150(systolic blood pressure) or < 60 or ≥ 100(diastolic blood pressure) Who had a medical history of alcohol and drug abuses. Who had taken a drug that has a control of metabolic rate (activatioh or inhibithion) in 30 days before the first taking of clinical testing durg. WHo smokes more than 20 eigarettes per day. Who took prescribed drugs or over-the-conuter durgs in 10 days before taking of very first clinical testing drug. Who participated in whole blood donation in 2 months before the first taking of clinical testing drugs or platelet donations in 1 month before the first taking to clinical testing drugs. Who has a potent to increase a danger by participating in the clinical trials or sho can interrupt interpretin test results by having serious or chronic medical and mental status or having issues in results of the screening examination. Who has a histroy of an extreme sensitivity of drugs that contain Rosiglitazone or dugs that have similar effect a Rosiglitazone(Pioglitazone), or drugs that contain the ingredients of Sitagliptin or thiazolidinediones drugs. Who has a serious heart failure or a congestive heart failure that must be drug-treated A patient with hepatopathy. A patient with wevere nephropathy. Who has diabetic ketoacidosis or a diaetic coma, or type 1 diabetes, or has history of acute metablic acidosis or ketoacidosis. A patient with serious infectious disease or severe injuries before and after a surgery. Who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose malabsorption or genetic disorders. Test subjects who is not willing or unable to comply with guidelines described in this protocol. A person who is not determined unsuitable to participate in this test by the researchers.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Min-Gul Kim, MD,PhD
Organizational Affiliation
Chonbuk National University Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Chonbuk National University Hospital
City
Jeonju-si
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32362346
Citation
Moon SJ, Yu KS, Kim MG. An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men. Clin Ther. 2020 Jun;42(6):1047-1057. doi: 10.1016/j.clinthera.2020.04.005. Epub 2020 Apr 30.
Results Reference
derived

Learn more about this trial

CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)

We'll reach out to this number within 24 hrs